EICHORPublic-registry site landscape for NCT07749586, “A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors”, a Advanced Solid Tumor study sponsored by Arvinas Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07749586 (registry record) |
| Study title | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors |
| Official title | A Phase 1/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ARV-6723 Administered as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors |
| Sponsor | Arvinas Inc. |
| Condition(s) | Advanced Solid Tumor |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 3 |
| Intervention(s) | ARV-6723, Pembrolizumab, SOC |
| Site countries | United States |
At Clinical Trial Site — one of the facilities listed on this trial — 3 other studies are actively recruiting Advanced Solid Tumor patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07749586.
Eichor generates a preliminary site-risk snapshot for NCT07749586 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
